Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Lung, Respiratory and Thoracic Cancer

First-line treatment of ALK-positive NSCLC

healthbook TIMES Oncology Hematology

Bouchaab H

doi: 10.36000/hbT.OH.2019.02.008

Genitourinary Cancer

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies

Eur J Cancer.

Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G

doi: 10.1016/j.ejca.2017.06.030.

Bruton's tyrosine kinase (BTK) as a promising target in solid tumors

Cancer Treat Rev.

Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E

doi: 10.1016/j.ctrv.2017.06.001.

Lung, Respiratory and Thoracic Cancer

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

JAMA Oncol.

Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R

doi: 10.1001/

RECOMMENDED

Skin Cancer

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

J Immunother.

Dimitriou F, Matter AV, Mangana J, Urosevic-Maiwald M, Micaletto S, Braun RP, French LE, Dummer R

doi: 10.1097/CJI.

Genitourinary Cancer

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Alexander Meisela,b

doi: 10.36000/hbT.OH.2019.02.007

Breast Cancer

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Oncologist.

Spring LM, Zangardi ML, Moy B, Bardia A

doi: 10.1634/

Endocrine and Neuroendocrine Tumors (NET)Skin Cancer

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

healthbook TIMES Oncology Hematology

Zihlera D, Vollmera K, Cozzio A

doi: 10.36000/hbT.OH.2019.01.003

Related content

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

First-line treatment of ALK-positive NSCLC

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies

Bruton's tyrosine kinase (BTK) as a promising target in solid tumors

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma